Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
Genmab inks $1.8B ProfoundBio buyout for would-be Elahere rival
The deal will give Genmab control of a midphase antibody-drug conjugate that could compete against AbbVie’s Elahere.
Nick Paul Taylor
Apr 3, 2024 5:32am
Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B
Feb 13, 2024 7:00am
Researchers plug a nanopore with gold to detect ovarian cancer
Feb 12, 2024 10:33am
Allarity loses rights to Novartis cancer drug over payments
Feb 2, 2024 9:09am
Laekna seeks regulatory path after phase 2 ovarian cancer fail
Jan 29, 2024 2:33pm
First-in-class drug halts breast and ovarian cancer in mice
Oct 27, 2023 7:45am